AGTR1 and metabolic syndrome: Particularly in hypertension accompanied by dyslipidemia, RAS inhibitors may exhibit anti-inflammatory, antifibrotic, and antioxidant effects in the kidneys by inhibiting the Gq signaling pathway through the AT1-LOX-1 complex in renal tubular cells and fibroblasts.